Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL).

Tisi MC, Ferrero S, Dogliotti I, Tecchio C, Carli G, Novo M, Stefani PM, Rattotti S, Balzarotti M, Marino D, Pelosini M, Romano A, Flenghi L, Zilioli VR, Calimeri T, Di Napoli A, Zanni M, Finolezzi E, Mosna F, Gini G, Mansueto G, Di Rocco A, Tomei G, Sgherza N, Olivieri J, Nassi L, Piazza F, Fama A, Greco A, Giannoccaro M, Mazzone AM, Visco C, Loseto G, Zaja F.

Hemasphere. 2019 Oct 22;3(6):e305. doi: 10.1097/HS9.0000000000000305. eCollection 2019 Dec.

2.

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.

Broccoli A, Casadei B, Chiappella A, Visco C, Tani M, Cascavilla N, Conconi A, Balzarotti M, Cox MC, Marino D, Goldaniga MC, Marasca R, Tecchio C, Patti C, Musuraca G, Devizzi L, Monaco F, Romano A, Fama A, Zancanella M, Paolini R, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Oncologist. 2019 Sep;24(9):1246-1252. doi: 10.1634/theoncologist.2018-0603. Epub 2019 Apr 2.

3.

Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.

Rattotti S, Ferretti VV, Rusconi C, Rossi A, Fogazzi S, Baldini L, Pioltelli P, Balzarotti M, Farina L, Ferreri AJM, Laszlo D, Speziale V, Varettoni M, Sciarra R, Morello L, Tedeschi A, Frigeni M, Defrancesco I, Zerbi C, Flospergher E, Nizzoli ME, Morra E, Arcaini L; “Rete Ematologica Lombarda” (REL - Hematology Clinical Network of Lombardy - Lymphoma Workgroup).

Hematol Oncol. 2019 Apr;37(2):160-167. doi: 10.1002/hon.2575. Epub 2019 Feb 22.

PMID:
30726562
4.

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.

Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).

Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17.

PMID:
29054815
5.

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.

Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U.

Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.

PMID:
28668386
6.

Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi.

Luminari S, Viel E, Ferreri AJM, Zaja F, Chimienti E, Musuraca G, Tucci A, Balzarotti M, Tani M, Salvi F, Pesce EA, Ferrari A, Liberati AM, Spadea A, Marino D, Bruno-Ventre M, Volpetti S, Bottelli C, Ravaioli E, Merli F, Spina M.

Hematol Oncol. 2018 Feb;36(1):68-75. doi: 10.1002/hon.2425. Epub 2017 May 19.

PMID:
28524259
7.

Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma.

Ceriani L, Martelli M, Gospodarowicz MK, Ricardi U, Ferreri AJ, Chiappella A, Stelitano C, Balzarotti M, Cabrera ME, Cunningham D, Guarini A, Zinzani PL, Giovanella L, Johnson PW, Zucca E.

Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):42-49. doi: 10.1016/j.ijrobp.2016.09.031. Epub 2016 Sep 28.

PMID:
27839910
8.

The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma).

Chauvie S, Bergesio F, Fioroni F, Brambilla M, Biggi A, Versari A, Guerra L, Storto G, Musto P, Luminari S, Cabras MG, Balzarotti M, Rigacci L, Martelli M, Vitolo U, Federico M, Gallamini A.

Phys Med. 2016 May;32(5):651-6. doi: 10.1016/j.ejmp.2016.04.004. Epub 2016 Apr 28.

PMID:
27133138
9.

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).

Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6.

PMID:
27132696
10.

B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).

Balzarotti M, Brusamolino E, Angelucci E, Carella AM, Vitolo U, Russo E, Congiu A, Gotti M, Massidda S, Botto B, Annechini G, Spina M, Re A, Zilioli VR, Merli F, Salvi F, Stelitano C, Bonfichi M, Rodari M, Murru R, Magagnoli M, Anastasia A, Mazza R, Giordano L, Santoro A.

Leuk Lymphoma. 2016 Oct;57(10):2375-81. doi: 10.3109/10428194.2016.1140161. Epub 2016 Feb 15.

PMID:
26879066
11.

Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients.

Crocchiolo R, Castagna L, Garciaz S, Fürst S, El Cheikh J, Sarina B, Bramanti S, Granata A, Vai A, Harbi S, Morabito L, Mohty B, Giordano L, Devillier R, Coso D, Balzarotti M, Chabannon C, Carlo-Stella C, Santoro A, Bouabdallah R, Blaise D.

Haematologica. 2015 Oct;100(10):e423-7. doi: 10.3324/haematol.2015.129452. Epub 2015 Jul 23. No abstract available.

12.

The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).

Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, Balzarotti M, Stelitano C, Spina M, Vitolo U, Stefoni V, Levis A, Gotti M, Rosaria S, Maria SP, Bosi A, Gallamini A.

Am J Hematol. 2015 Jun;90(6):499-503. doi: 10.1002/ajh.23994. Epub 2015 May 10.

13.

High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant.

Castagna L, Crocchiolo R, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, Chiti A, Mauro E, Gandolfi S, Todisco E, Balzarotti M, Anastasia A, Magagnoli M, Brusamolino E, Santoro A.

Bone Marrow Transplant. 2015 Apr;50(4):499-504. doi: 10.1038/bmt.2014.304. Epub 2015 Jan 26.

PMID:
25621797
14.

The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.

Rossi G, Marcheselli L, Dondi A, Bottelli C, Tucci A, Luminari S, Arcaini L, Merli M, Pulsoni A, Boccomini C, Puccini B, Micheletti M, Martinelli G, Rossi A, Zilioli VR, Bozzoli V, Balzarotti M, Bolis S, Cabras MG, Federico M.

Am J Hematol. 2015 Jan;90(1):56-61. doi: 10.1002/ajh.23872. Epub 2014 Nov 19.

15.

Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas.

Castagna L, Bramanti S, Furst S, Giordano L, Crocchiolo R, Sarina B, Mauro E, Morabito L, Bouabdallah R, Coso D, Balzarotti M, Broussais F, El-Cheikh J, Stella CC, Brusamolino E, Blaise D, Santoro A.

Bone Marrow Transplant. 2014 Dec;49(12):1475-80. doi: 10.1038/bmt.2014.197. Epub 2014 Sep 15. Erratum in: Bone Marrow Transplant. 2014 Dec;49(12):1552.

PMID:
25222502
16.

[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.

Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U, Stelitano C, Brusamolino E, Cabras MG, Rigacci L, Balzarotti M, Salvi F, Montoto S, Lopez-Guillermo A, Finolezzi E, Pileri SA, Davies A, Cavalli F, Giovanella L, Johnson PW.

J Clin Oncol. 2014 Jun 10;32(17):1769-75. doi: 10.1200/JCO.2013.51.7524. Epub 2014 May 5.

PMID:
24799481
17.

MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years.

Ferreri AJ, Ciceri F, Brandes AA, Montanari M, Balzarotti M, Spina M, Ilariucci F, Zaja F, Stelitano C, Bobbio F, Corazzelli G, Baldini L, Reni M.

Neurology. 2014 Apr 15;82(15):1370-3. doi: 10.1212/WNL.0000000000000314. Epub 2014 Mar 14.

PMID:
24634458
18.

The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).

Luminari S, Biasoli I, Versari A, Rattotti S, Bottelli C, Rusconi C, Merli F, Spina M, Ferreri AJ, Zinzani PL, Gallamini A, Franceschetto A, Boccomini C, Franceschetti S, Salvi F, Raimondo FD, Carella AM, Micol Q, Balzarotti M, Musto P, Federico M.

Ann Oncol. 2014 Feb;25(2):442-7. doi: 10.1093/annonc/mdt562. Epub 2014 Jan 10.

19.

Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma.

Crocchiolo R, Castagna L, Fürst S, El-Cheikh J, Faucher C, Oudin C, Granata A, Bouabdallah R, Coso D, Chabannon C, Balzarotti M, Santoro A, Blaise D.

Bone Marrow Transplant. 2013 Feb;48(2):249-52. doi: 10.1038/bmt.2012.116. Epub 2012 Jun 25.

PMID:
22732704
20.

Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma.

Spina M, Balzarotti M, Uziel L, Ferreri AJ, Fratino L, Magagnoli M, Talamini R, Giacalone A, Ravaioli E, Chimienti E, Berretta M, Lleshi A, Santoro A, Tirelli U.

Oncologist. 2012;17(6):838-46. doi: 10.1634/theoncologist.2011-0417. Epub 2012 May 18.

21.

Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).

Rigacci L, Puccini B, Cortelazzo S, Gaidano G, Piccin A, D'Arco A, Freilone R, Storti S, Orciuolo E, Zinzani PL, Zaja F, Bongarzoni V, Balzarotti M, Rota-Scalabrini D, Patti C, Gobbi M, Carpaneto A, Liberati AM, Bosi A, Iannitto E.

Ann Hematol. 2012 Jul;91(7):1013-22. doi: 10.1007/s00277-012-1422-5. Epub 2012 Feb 15.

PMID:
22349722
22.

Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.

Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A, Ivanov V, Schiano JM, Santoro A, Chabannon C, Balzarotti M, Blaise D, Bouabdallah R.

Haematologica. 2012 Jul;97(7):1073-9. doi: 10.3324/haematol.2011.056051. Epub 2012 Jan 22.

23.

Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers.

Zaja F, De Luca S, Vitolo U, Orsucci L, Levis A, Salvi F, Rusconi C, Ravelli E, Tucci A, Bottelli C, Balzarotti M, Brusamolino E, Bonfichi M, Pileri SA, Sabattini E, Volpetti S, Monagheddu C, Vacca A, Ria R, Fanin R.

Haematologica. 2012 Mar;97(3):416-22. doi: 10.3324/haematol.2011.051813. Epub 2011 Nov 4.

24.

First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.

Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E.

J Clin Oncol. 2011 Jul 10;29(20):2766-72. doi: 10.1200/JCO.2010.31.4187. Epub 2011 Jun 6.

25.

Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.

Arcaini L, Laszlo D, Rizzi S, Balzarotti M, Antoniazzi F, Zilioli VR, Guggiari E, Farina L, Todisco E, Bonfichi M, Alamos SM, Rossi G, Martinelli G, Morra E.

Leuk Res. 2011 Jun;35(6):712-4. doi: 10.1016/j.leukres.2010.12.036. Epub 2011 Jan 26.

PMID:
21276613
26.

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F; International Extranodal Lymphoma Study Group (IELSG).

Lancet. 2009 Oct 31;374(9700):1512-20. doi: 10.1016/S0140-6736(09)61416-1. Epub 2009 Sep 18.

27.

Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy.

Castagna L, Bramanti S, Balzarotti M, Sarina B, Todisco E, Anastasia A, Magagnoli M, Mazza R, Nozza A, Giordano L, Rodari M, Rinifilo E, Chiti A, Santoro A.

Br J Haematol. 2009 May;145(3):369-72. doi: 10.1111/j.1365-2141.2009.07645.x. Epub 2009 Mar 5.

PMID:
19344403
28.

Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma.

Castagna L, Sarina B, Todisco E, Magagnoli M, Balzarotti M, Bramanti S, Mazza R, Anastasia A, Bacigalupo A, Aversa F, Soligo D, Giordano L, Santoro A.

Biol Blood Marrow Transplant. 2009 Apr;15(4):432-8. doi: 10.1016/j.bbmt.2008.12.506. Epub 2009 Feb 12.

29.

What is the best option to cure patients with resistant/relapsing Hodgkin's disease?

Magagnoli M, Balzarotti M, Castagna L, Demarco M, Santoro A.

Curr Stem Cell Res Ther. 2006 Sep;1(3):419-24. Review.

PMID:
18220885
30.

Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines.

Ciusani E, Balzarotti M, Calatozzolo C, de Grazia U, Boiardi A, Salmaggi A, Croci D.

Oncol Res. 2007;16(10):453-63.

PMID:
18196869
31.

High relapse rate after a brief chemotherapy course and involved-field radiotherapy in early-stage Hodgkin lymphoma.

Magagnoli M, Balzarotti M, Siracusano LV, Spina M, Isa L, Morenghi E, Tirelli U, Santoro A.

Leuk Lymphoma. 2007 Dec;48(12):2444-6. Epub 2007 Oct 9. No abstract available.

PMID:
17943600
32.

IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients.

Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M, Capizzuto R, Morenghi E, Castagna L, Tirelli U, Santoro A.

Bone Marrow Transplant. 2007 Dec;40(11):1019-25. Epub 2007 Oct 1.

PMID:
17906705
33.

CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.

Todisco E, Castagna L, Sarina B, Mazza R, Magagnoli M, Balzarotti M, Nozza A, Siracusano L, Timofeeva I, Anastasia A, Demarco M, Santoro A.

Eur J Haematol. 2007 Feb;78(2):111-6.

PMID:
17313558
34.

In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas.

Balzarotti M, Fontana F, Marras C, Boiardi A, Croci D, Ciusani E, Salmaggi A.

Oncol Res. 2006;16(5):245-50.

PMID:
17294805
35.

Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.

Todisco E, Castagna L, Sarina B, Mazza R, Anastasia A, Balzarotti M, Banna G, Tirelli U, Soligo D, Santoro A.

Eur J Haematol. 2007 Apr;78(4):322-9. Epub 2007 Jan 23.

PMID:
17253967
36.

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.

Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M.

Haematologica. 2007 Jan;92(1):35-41.

37.

Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.

Castagna L, Magagnoli M, Balzarotti M, Sarina B, Siracusano L, Nozza A, Todisco E, Bramanti S, Mazza R, Russo F, Timofeeva I, Santoro A.

Am J Hematol. 2007 Feb;82(2):122-7.

38.

MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.

Ferreri AJ, Dell'Oro S, Foppoli M, Bernardi M, Brandes AA, Tosoni A, Montanari M, Balzarotti M, Spina M, Ilariucci F, Zaja F, Stelitano C, Bobbio F, Corazzelli G, Baldini L, Ponzoni M, Picozzi P, Caligaris Cappio F, Reni M.

Neurology. 2006 May 9;66(9):1435-8.

PMID:
16682682
39.

Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas.

Tirelli U, Balzarotti M, Uziel L, Ferreri AJ, Santoro A, Spina M.

Ann Oncol. 2006 Mar;17(3):533. Epub 2005 Nov 15. No abstract available.

40.

Primary mediastinal B-cell lymphoma with sclerosis: report of 11 cases treated with intensified-CHOP plus radiotherapy.

Siracusano L, Balzarotti M, Magagnoli M, Castagna L, Rahal D, Santoro A.

Am J Hematol. 2005 Apr;78(4):312-3.

41.

In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma.

Ciusani E, Croci D, Gelati M, Calatozzolo C, Sciacca F, Fumagalli L, Balzarotti M, Fariselli L, Boiardi A, Salmaggi A.

J Neurooncol. 2005 Jan;71(1):19-25.

PMID:
15719269
42.

Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines.

Balzarotti M, Ciusani E, Calatozzolo C, Croci D, Boiardi A, Salmaggi A.

Oncol Res. 2004;14(7-8):325-30.

PMID:
15301423
43.

Single-agent high-dose melphalan followed by peripheral blood stem cell (PBSC) in lymphoma patients: an effective, and well-tolerated conditioning regimen.

Magagnoli M, Castagna L, Bramanti S, Balzarotti M, Santoro A.

Bone Marrow Transplant. 2004 May;33(10):1067-8. No abstract available.

PMID:
15129236
44.

Idiopathic thrombocytopenic purpura and splenic marginal-zone B-cell lymphoma: a casual correlation?

Magagnoli M, Balzarotti M, Castagna L, Rahal D, Siracusano L, Nozza A, Santoro A.

Leuk Lymphoma. 2003 Sep;44(9):1639-40. No abstract available.

PMID:
14565674
45.

Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour.

Bertuzzi A, Castagna L, Quagliuolo V, Ginanni V, Compasso S, Magagnoli M, Balzarotti M, Nozza A, Siracusano L, Timofeeva I, Sarina B, Parra HS, Santoro A.

Br J Cancer. 2003 Oct 6;89(7):1159-61.

46.

High-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly versus younger lymphoma patients: a matched analysis.

Magagnoli M, Castagna L, Timofeeva I, Balzarotti M, Santoro A.

Leuk Lymphoma. 2003 Aug;44(8):1439-40. No abstract available.

PMID:
12952242
47.

Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution.

Magagnoli M, Castagna L, Balzarotti M, Sarina B, Timofeeva I, Bertuzzi A, Compasso S, Nozza A, Siracusano L, Santoro A.

Am J Hematol. 2003 Aug;73(4):267-72.

48.
49.

Lymphomas.

Santoro A, Balzarotti M, Castagna L.

Cancer Chemother Biol Response Modif. 2002;20:391-418. Review. No abstract available.

PMID:
12703217
50.

Comprehensive geriatric evaluation in elderly patients with lymphoma: feasibility of a patient-tailored treatment plan.

Bernardi D, Milan I, Balzarotti M, Spina M, Santoro A, Tirelli U.

J Clin Oncol. 2003 Feb 15;21(4):754; author reply 755. No abstract available.

PMID:
12586816

Supplemental Content

Loading ...
Support Center